Cytotheryx, Inc. announced today it has acquired the intellectual property assets of Ambys Medicines, Inc., which will now become part of our portfolio.

The Cytotheryx team is committed to community volunteering. We’re proud to have spent time volunteering together to keep our city clean and beautiful.

The Cytotheryx team is humbled and honored to have been selected as a 2022 Early Stage BOLD Award Winner at the 10th Annual BOLD Awards!

Cytotheryx is excited to share we’ve been selected as a finalist for the 10th Annual BOLD Awards, which honor innovative and inspirational organizations.

We’re proud to be part of the cell and gene therapy community, and to participate in conferences like Meeting on the Mesa where we can build partnerships.

The Medical Alley Association interviewed Cytotheryx CEO Dr. John Swart to discuss Cytotheryx’ innovative work. Find the whole conversation here.

Regenerative Medicine Minnesota (RMM) has awarded Cytotheryx with the prestigious biobusiness development grant, which will enable our continued focused innovation.

Rochester Area Economic Development Inc. (RAEDI) has honored Cytotheryx with a Recognizing Award Valuing Entrepreneurs (R.A.V.E.) award.

We’re honored to have received a grant from Launch Minnesota Innovation Grants, which honors promising innovative, scalable technology businesses in the state.

We are committed to our work and the wellness of our communities, and will remain so during this challenging and uncertain time of COVID-19.

Cytotheryx received a full AAALAC International accreditation, the highest certification level. Learn what this accreditation means and how we achieved it.